Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUCNR1 | Q9BXA5 | 9/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.44 |
| ▸ | CFD | P00746 | 6/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
| ▸ | F11 | P03951 | 1/20 | 0.40 |
| ▸ | TPSB2 | P20231 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16410357 | 0.94 | HDAC1 (0.41) | SUCNR1HDAC1CFDNR1H4F11 | |
| SCHEMBL16397314 | 0.86 | SUCNR1 (0.49) | SUCNR1HDAC1CFDNR1H4F11 | |
| SCHEMBL16396992 | 0.86 | SUCNR1 (0.60) | SUCNR1HDAC1CFDNR1H4F11 | |
| SCHEMBL17764462 | 0.84 | SUCNR1 (0.48) | SUCNR1HDAC1CFDNR1H4F11 | |
| SCHEMBL16403623 | 0.84 | CFD (0.56) | SUCNR1CFDNR1H4F11TPSB2 | |
| SCHEMBL16397193 | 0.83 | SUCNR1 (0.47) | SUCNR1HDAC1CFDNR1H4F11 | |
| SCHEMBL16396862 | 0.81 | SUCNR1 (0.49) | SUCNR1HDAC1CFDNR1H4F11 | |
| SCHEMBL17764465 | 0.80 | CFD (0.56) | SUCNR1HDAC1CFDNR1H4F11 | |
| SCHEMBL21455909 | 0.80 | SUCNR1 (0.46) | SUCNR1HDAC1CFDNR1H4F11 | |
| SCHEMBL16396451 | 0.80 | HDAC1 (0.44) | SUCNR1HDAC1CFDNR1H4F11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160145247-A1 | Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof | NOVARTIS AG (CH) | 2016-05-26 | — | — | US | disclosed |
| EP-3022182-A1 | AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF | Novartis AG (CH) | 2016-05-25 | — | — | EP | disclosed |
| WO-2015009977-A1 | AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2015-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145247-A1 | Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof | CFD, CFH, CFB | SUCNR1 4670/4885HDAC1 3377/4885CFD 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.